Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B
Conditions
Keywords
Multiple Endocrine Neoplasia, Medullary Thyroid Carcinoma, Molecularly-Targeted Therapy, Pediatric, Pharmacokinetics
Brief summary
Background: * Medullary thyroid carcinoma (MTC) is common in people with a genetic disorder called multiple endocrine neoplasia (MEN). * Vandetanib is an experimental drug that blocks a defective protein receptor (rearranged during transfection (RET) receptor) found on the surface of cancer cells in people with MEN. It is thought that this protein is a primary cause of MTC in people with MEN. Objectives: * To study the activity of Vandetanib in children and adolescents with MEN-related MTC by measuring the change in tumor size, in blood levels of proteins produced the tumor (calcitonin and carcinoembryonic antigen (CEA) and in tumor-related diarrhea. * To determine the safety and tolerability of Vandetanib in children and adolescents. * To study how the body handles Vandetanib in children and adolescents. * To determine the effect of Vandetanib on the survival of children and adolescents with MTC. Eligibility: -Children and adolescents 5 to 18 years of age with MTC whose tumor cannot be surgically removed or has grown back after treatment or has metastasized (spread beyond the thyroid gland). Design: * Patients take Vandetanib once a day in 28-day cycles. The first patients enrolled in the study are started on a low dose of Vandetanib to determine tolerability. * Patients have periodic blood tests, electrocardiograms, and blood pressure measurements to look for side effects of Vandetanib. * Blood tests and imaging scans (magnetic resonance imaging (MRI), computed tomography (CT), bone and octreoscan) are done every 8 weeks for the first 32 weeks of treatment and then every 16 weeks for the duration of the treatment period. * Patients who have tumor-related diarrhea keep a daily record of the number and consistency of bowel movements.
Detailed description
BACKGROUND: Hereditary medullary thyroid carcinoma (MTC), which is a rare calcitonin-producing tumor arising from the parafollicular C cells of the thyroid, is often a manifestation of multiple endocrine neoplasia (MEN) types 2A and 2B and can be detected in children as young as five years in MEN 2A and one year in those with MEN 2B MEN results from an activating mutation in the rearranged during transfection (RET) proto-oncogene resulting in a constitutively activated receptor tyrosine kinase (RTK) Vandetanib is an orally bioavailable multi-RTK inhibitor that blocks the mutant RET gene product and has anti-tumor activity in adults with hereditary MTC OBJECTIVES: To assess the activity of vandetanib in children and adolescents with hereditary MTC using Response Evaluation Criteria in Solid Tumors (RECIST) (primary endpoint), tumor biomarkers and tumor-related diarrhea To assess the safety and tolerance of vandetanib in children and adolescents at a dose equivalent to the recommended dose in adults To assess the pharmacokinetics of vandetanib at steady state in children and adolescents Secondary objectives include monitoring progression-free and overall survival, assessing RET, epidermal growth factor receptor (EGFR), Vascular endothelial growth factor (VEGFR) and somatostatin receptor expression in archival tumor tissue, assessing changes in deoxyribonucleic acid (DNA) mutations in RET in tumor tissue vs germ line in PBMC and after treatment; assessing gene expression and gains/losses of DNA in tumor tissue at baseline, during treatment and at the time of progression; establishment of pediatric MTC cell lines sensitive and resistant cells lines in vitro ELIGIBILITY: Children and adolescents 5 to 18 years of age (inclusive) with unresectable, recurrent or metastatic hereditary medullary thyroid carcinoma Measurable disease by RECIST (Response Evaluation Criteria in Solid Tumors) DESIGN: Vandetanib will be administered as a once daily dose, continuously (1 cycle equals 28 days) at a dose of 150 mg,m(2), per day To ensure the safety of the adult dose in children and adolescents, a limited intra-patient dose escalation will be performed in the initial cohort of patients, with older patients (13 to18 yrs) being studied before younger patients (5 to12 yrs) Patients wil be enrolled at a dose of 100mg, m(2), per day (180 mg per day in adults) for two 28 day cycles and escalated to 150 mg, m(2), per day (270 mg, per day in adults) on cycle 3, if dose limiting toxicity was not observed at the lower dose. If the 150mg, m(2), per day dose level is tolerable on cycles 3 and 4, all subsequent patients will be enrolled at this dose level Pharmacokinetics of vandetanib will be studied at steady state at the end of cycle 2 and trough levels will be obtained prior to the second dose on cycle 1, and on day 1 of cycles 2-5. Responsible of measurable tumors will be assessed by RECIST. Biomarker and clinical response will also be monitored. Twenty one patients will be studied to determine if the response rate in children and adolescents with hereditary MTC is consistent with the 28 percent objective response rate in adults
Interventions
DRUGVandetanib
once daily continuously (28 day cycles)
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
5 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: Age: Participants must be 5 to 18 years of age, inclusive. The first cohort of 3 to 6 participants enrolled on the trial will be at least 13 years of age. Diagnosis: Hereditary (Multiple endocrine neoplasia, type 2A (MEN 2A) or Multiple endocrine neoplasia, type 2B (MEN 2B) medullary thyroid carcinoma (histologically confirmed) that is unresectable, recurrent or metastatic. Participants must have previously had a characteristic germline mutation in the rearranged during transfection (RET) proto-oncogene documented. Results of the germline mutation testing will be obtained from the referring institution. Participants must have measurable disease as defined in Response Evaluation Criteria in Solid Tumors (RECIST) as the presence of at least one lesion that can be accurately measured in at least one dimension with longest diameter of at least 20 mm using conventional techniques or at least 10 mm with spiral computed tomography (CT) scan. Superficial (easily palpable) lymph nodes will be considered measurable. Participants must be able to take one of the oral formulations of vandetanib. Prior therapy: There are no standard chemotherapy regimens known to be effective for medullary thyroid carcinoma (MTC). Therefore, previously untreated participants are eligible if their tumor(s) are not surgically resectable. Participants must be at least 4 weeks from prior surgical procedures and surgical incisions must be healed. Participants must have had their last fraction of external beam radiation therapy at least 4 weeks prior to enrollment. Participants must have had their last dose of cytotoxic chemotherapy at least 28 days prior to enrollment, their last dose of biological therapy, such as biological response modifiers (e.g., cytokines), immunomodulatory agents, vaccines, differentiating agents, used to treat their cancer at least 7 days prior to enrollment, their last dose of a monoclonal antibody at least 30 days prior to enrollment, and their last dose of any investigational agent at least 30 days prior to enrollment. Participants must have received their last dose of short acting colony stimulating factor, such as filgrastim or sargramostim at least 72 hours prior to enrollment and their last dose of long-acting colony stimulating factors, such as polyethylene glycol (PEG)-filgrastim at least 7 days prior to enrollment. Participants must have recovered from the acute toxic effects of prior therapy to a grade 1 (Common Terminology Criteria for Adverse Events (CTCAE) v.3.0) level prior to enrollment. Performance Status: Lansky (for participants 10 years of age or younger) or Karnofsky (for participants older than 10 years) performance score greater than 50 Concomitant Medications: Participants who have previously had a thyroidectomy should be on thyroid hormone replacement therapy. Hematological Function: The peripheral absolute neutrophil count must be at least 1,500 micro liters and the platelet count must be at least 100,000 micro liters within 72 hours prior to enrollment. Coagulation: Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) must not be more than 1.5 x ULN within 72 hours prior to enrollment. PT and PTT should drawn by venipuncture, rather than from a central venous catheter when feasible. Hepatic Function: Bilirubin must not be more than 1.5 x ULN and the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must not be more than 2.5 x ULN within 72 hours prior to enrollment. AST and ALT may be up to 5 x ULN within 72 hours prior to enrollment in participants with hepatic metastases. Renal Function: Participants must have an age-adjusted normal serum creatinine or a creatinine clearance of at least 60 ml/min/1.73 m\^2. Birth Control: Participants of child-bearing or child-fathering potential must be willing to use a medically effective form of birth control, which includes abstinence, while taking vandetanib and for 2 months after the last dose. Negative pregnancy test for women of childbearing potential. Informed Consent: Participants who are 18 years of age or legal guardians of participants who are younger than 18 years must sign an informed consent for the Pediatric Oncology Branch (POB) Screening Protocol prior to participating in studies required to determine eligibility for this trial. After confirmation of eligibility, participants or legal guardians of minor participants must sign an informed consent document for this trial, indicating that they are aware of the investigational nature of the proposed treatment, the risks and benefits of participating and the alternatives to participating.
Exclusion criteria
Pregnant or breast feeding females because the anti-angiogenic properties of vandetanib may be harmful to the developing fetus or nursing infant. Participants with pheochromocytoma as evidenced by elevated plasma free metanephrines. Electrolytes: Participants with a serum potassium less than 3.5 mmol/L or a serum calcium or magnesium below the lower limits of normal. Correction of these electrolyte abnormalities with supplements is allowed. Cardiac: Participants with a history of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, uncontrolled atrial fibrillation, left bundle branch block) that is symptomatic or requires treatment (except for controlled atrial fibrillation) Participants with a history of congenitally prolonged Corrected QT Interval (QTc), a first degree relative with unexplained sudden death under 40 years of age, or a measured QTc (Bazett's correction) longer than 480 msec on electrocardiogram (ECG). ECGs should be performed after correction of electrolyte abnormalities. Participants with a prolonged QTc should have a repeat ECG at least 24 hour after the first, and the mean of the 2 QTcs should not exceed 480 msec. Participants who experienced QTc prolongation with other medications requiring discontinuation of that medication. Participants receiving a medication that has a known risk of QTc prolongation within 14 days (28 days for levomethadyl) of enrollment. Hypertension: Diastolic blood pressure above the 95% for age on at least 2 of 3 measurements with an appropriate-size cuff or patients who are currently taking anti-hypertensive therapy. Other clinically severe or uncontrolled systemic illness that could compromise the participants ability to tolerate vandetanib or could compromise study procedures or endpoints.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Percentage of Participants With an Objective Response Defined as a Complete Response (CR) or Partial Response (PR) | Patients were evaluated for response after every 2 cycles x 4 (prior to cycles 1, 3, 5, 7, and 9) and then after every 4 cycles X 1 (prior to cycle 13) and then every 6 cycles (prior to cycle 19, 25, 31, etc). Response was followed for an median of 59 mon | Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Progressive Disease is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. |
| Maximum Tolerated Dose (MTD) | During Cycle 1 and Cycle 2, approximately 56 days | The MTD is the highest dose of Vandetanib tolerated at which a participant experienced a dose limiting toxicity (DLT) during the first two cycles of drug. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change in Calcitonin (CTN) Biomarker Response After Cycle 1 | Cycle 1 (28 days) | Blood was collected from participants and measured with an Chemiluminescence immunoassay. Calcitonin upper limit of normal is \<10 pg/mL. A decline in CTN is defined as a ≥50% increase (e.g. tumor growth or progression) in the CTN level after treatment in cycle 1. |
| Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | Date treatment consent signed to date off study, approximately 142 months and 8 days. | Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
| Area Under the Concentration Time Curve (AUC 0-24h) | Cycle 1, Pre-dose and then 1, 2, 4, 6, 8, 10 and 24 hour post dose. | The AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption. |
| Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Every 2 cycles x 4 (prior to cycles 1, 3, 5, 7 and 9), prior to cycle 13, and then every 6 cycles (prior to cycle 19, 25, 31, etc). Patients were followed for response for a median of 59 months. | Blood was collected from participants and measured with an Axsym Analyzer then Immulite CEA method and assessed by the following response criteria. Partial Response (PR) is a ≥50% decrease in the CEA level relative to the baseline level, confirmed with a repeat CEA level at least 4 weeks apart. Progression (P) is a ≥50% increase in the CEA relative to the prior value on 2 consecutive measurements at least 4 weeks apart. The patient must have been taking vandetanib for 4 weeks prior to the first measurements and must have continued to take the drug through the time that the second measurement was drawn. Stable (S) is a \<50% increase or decrease in CEA level relative to the baseline level. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With a Dose Limiting Toxicity (DLT) | up to Cycle 3 (each Cycle is 28 days) | Hematologic Dose-Limiting Toxicity (H-DLT) is: Neutrophil count below 1,000/μL (grade 3) on 2 consecutive measurements drawn at least 72 hours apart OR a single neutrophil count below 500/μL (grade 4); Platelet count below 50,000/μL (grade 3) on 2 consecutive measurements drawn at least 72 hours apart OR a single platelet count below 25,000/μL (grade 4); A platelet transfusion administered when platelet count is below 50,000/μL is dose limiting thrombocytopenia, unless the transfusion is being administered for perioperative coverage; Grade 3 or 4 decrease in hemoglobin that can be corrected to at least 8.0 g/dl (grade 2) by transfusion of red blood cells is not a dose-limiting toxicity. Grade 3 or 4 hemolysis is a dose-limiting toxicity if it is judged to be vandetanib-related. Non-Hematologic Dose-Limiting Toxicity is any grade 3 or higher non-hematologic toxicity, with some exceptions such as Grade 3 nausea that is controlled by symptomatic treatment with anti-emetics. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Vandetanib: First 100 mg/m^2, Then 150 mg/m^2 All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 100 mg/m\^2/day, then 150 mg/m\^2. | 5 |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 100 mg/m\^2/day, then 150 mg/m\^2, followed by 67 mg/m\^2. | 1 |
| Vandetanib 100 mg/m^2 All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 100 mg/m\^2/day. | 5 |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 100 mg/m\^2/day, then 150 mg/m\^2, followed by 100 mg/m\^2. | 1 |
| Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 100 mg/m\^2/day, then 63 mg/m\^2, then 42 mg/m\^2, then 21 mg/m\^2, then 42 mg/m\^2, followed by 21 mg/m\^2. | 1 |
| Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 100 mg/m\^2/day, then 70 mg/m\^2. | 1 |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 100 mg/m\^2/day, then 150 mg/m\^2, followed by 200 mg/m\^2. | 1 |
| Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 100 mg/m\^2/day, then 150 mg/m\^2, then 100 mg/m\^2, then 150 mg/m\^2, then 100 mg/m\^2, followed by 150 mg/m\^2. | 1 |
| Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg All participants who received a starting dose of Vandetanib administered as a once daily dose, continuously (1 cycle = 28 days) at a dose of 150 mg/m\^2/day, then 100 mg/m\^2. | 1 |
| Total | 17 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 |
|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Disease progression on study | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Overall Study | Getting vandetanib via the REMS program | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Overall Study | transferred to another protocol | 2 | 1 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | Vandetanib 100 mg/m^2 | Vandetanib: First 100 mg/m^2, Then 150 mg/m^2 | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | Total | Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg |
|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 1 Participants | 1 Participants | 5 Participants | 5 Participants | 1 Participants | 1 Participants | 17 Participants | 1 Participants | 1 Participants | 1 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 16.8 years STANDARD_DEVIATION 0 | 15.4 years STANDARD_DEVIATION 0 | 12.52 years STANDARD_DEVIATION 2.81 | 15.14 years STANDARD_DEVIATION 2.07 | 16.7 years STANDARD_DEVIATION 0 | 12.1 years STANDARD_DEVIATION 0 | 14.50 years STANDARD_DEVIATION 2.44 | 17.3 years STANDARD_DEVIATION 0 | 13.2 years STANDARD_DEVIATION 0 | 11.3 years STANDARD_DEVIATION 0 |
| Baseline Performance Status | 100 scores on a scale | 80 scores on a scale | 80 scores on a scale | 100 scores on a scale | 80 scores on a scale | 100 scores on a scale | 100 scores on a scale | 90 scores on a scale | 100 scores on a scale | 100 scores on a scale |
| Calcitonin (CTN) at Enrollment Patient 1 | 0 pg/mL | 18,300 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 10 | 0 pg/mL | 0 pg/mL | 57,800 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 11 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 13,300 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 12 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 6,900 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 13 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 24,200 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 14 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 21,400 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 15 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 800 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 16 | 47.700 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 17 | 0 pg/mL | 0 pg/mL | 16,064 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 2 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 67,100 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 3 | 0 pg/mL | 0 pg/mL | 4,500 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 4 | 0 pg/mL | 0 pg/mL | 25,900 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 5 | 0 pg/mL | 0 pg/mL | 18,900 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 6 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 4,600 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 7 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 2,000 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 8 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 3,500 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Calcitonin (CTN) at Enrollment Patient 9 | 0 pg/mL | 0 pg/mL | 0 pg/mL | 500 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL | 0 pg/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 1 | 0 ng/mL | 341.1 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 10 | 0 ng/mL | 0 ng/mL | 801.3 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 11 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 133.4 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 12 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 28.4 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 13 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 244.5 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 14 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 84 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 15 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 5.1 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 16 | 60 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 17 | 0 ng/mL | 0 ng/mL | 863 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 2 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 130.6 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 3 | 0 ng/mL | 0 ng/mL | 444.2 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 4 | 0 ng/mL | 0 ng/mL | 247.1 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 5 | 0 ng/mL | 0 ng/mL | 60.2 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 6 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 17.7 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 7 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 6.8 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 8 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 115.5 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Carcinoembryonic Antigen (CEA) at Enrollment Patient 9 | 0 ng/mL | 0 ng/mL | 0 ng/mL | 8.1 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL | 0 ng/mL |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 0 Participants | 5 Participants | 0 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 1 Participants | 1 Participants | 4 Participants | 3 Participants | 0 Participants | 1 Participants | 12 Participants | 1 Participants | 1 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 0 Participants | 1 Participants | 4 Participants | 5 Participants | 1 Participants | 1 Participants | 15 Participants | 1 Participants | 1 Participants | 1 Participants |
| Region of Enrollment United States | 1 participants | 1 participants | 5 participants | 5 participants | 1 participants | 1 participants | 1 participants | 1 participants | 1 participants | 1 participants |
| Sex: Female, Male Female | 0 Participants | 1 Participants | 3 Participants | 4 Participants | 1 Participants | 0 Participants | 9 Participants | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 1 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 8 Participants | 1 Participants | 1 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 1 | 0 / 5 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 |
| other Total, other adverse events | 5 / 5 | 1 / 1 | 4 / 5 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 | 1 / 1 |
| serious Total, serious adverse events | 2 / 5 | 0 / 1 | 1 / 5 | 1 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 | 0 / 1 |
Outcome results
Primary
Maximum Tolerated Dose (MTD)
The MTD is the highest dose of Vandetanib tolerated at which a participant experienced a dose limiting toxicity (DLT) during the first two cycles of drug.
Time frame: During Cycle 1 and Cycle 2, approximately 56 days
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Maximum Tolerated Dose (MTD) | 100 mg/m^2/day |
Primary
Overall Percentage of Participants With an Objective Response Defined as a Complete Response (CR) or Partial Response (PR)
Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete Response is disappearance of all target lesions. Partial Response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. Progressive Disease is at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Patients were evaluated for response after every 2 cycles x 4 (prior to cycles 1, 3, 5, 7, and 9) and then after every 4 cycles X 1 (prior to cycle 13) and then every 6 cycles (prior to cycle 19, 25, 31, etc). Response was followed for an median of 59 mon
Population: This is the analysis of all 17 patients across dosing groups. Because dosing for each patient was adjusted over time based on toxicity and often patients did not have a radiographic response until they had a number of cycles of treatment, we combined all dosing groups when calculating response rate.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Overall Percentage of Participants With an Objective Response Defined as a Complete Response (CR) or Partial Response (PR) | 59 percentage of participants |
Secondary
Area Under the Concentration Time Curve (AUC 0-24h)
The AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.
Time frame: Cycle 1, Pre-dose and then 1, 2, 4, 6, 8, 10 and 24 hour post dose.
Population: All 11 subjects who had PK analysis were receiving a dose of 100mg/m\^2/dose at the time that the PK analysis was done. All participants are grouped together because this data was performed during cycle 1 and was not collected for the patient who received 150mg/m\^2 during cycle 1.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| All Participants | Area Under the Concentration Time Curve (AUC 0-24h) | 16 mcg*h/mL |
Secondary
Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response
Blood was collected from participants and measured with an Axsym Analyzer then Immulite CEA method and assessed by the following response criteria. Partial Response (PR) is a ≥50% decrease in the CEA level relative to the baseline level, confirmed with a repeat CEA level at least 4 weeks apart. Progression (P) is a ≥50% increase in the CEA relative to the prior value on 2 consecutive measurements at least 4 weeks apart. The patient must have been taking vandetanib for 4 weeks prior to the first measurements and must have continued to take the drug through the time that the second measurement was drawn. Stable (S) is a \<50% increase or decrease in CEA level relative to the baseline level.
Time frame: Every 2 cycles x 4 (prior to cycles 1, 3, 5, 7 and 9), prior to cycle 13, and then every 6 cycles (prior to cycle 19, 25, 31, etc). Patients were followed for response for a median of 59 months.
Population: Patients with CEA \<2x upper limit of normal at baseline were not evaluable for this measure.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| All Participants | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 0 Participants |
| All Participants | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 1 Participants |
| All Participants | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 1 Participants |
| All Participants | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 3 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 1 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 0 Participants |
| Vandetanib 100 mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 3 Participants |
| Vandetanib 100 mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 1 Participants |
| Vandetanib 100 mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 1 Participants |
| Vandetanib 100 mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 1 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 1 Participants |
| Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 0 Participants |
| Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 1 Participants |
| Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 0 Participants |
| Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 1 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 1 Participants |
| Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | Not Evaluable (NE) | 0 Participants |
| Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | <50% decrease/<50% increase | 0 Participants |
| Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | >50% increase | 0 Participants |
| Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | Number of Participants With an Increase or Decrease in Carcinoembryonic Antigen (CEA) Biomarker Response | ≥50% decrease | 1 Participants |
Secondary
Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0)
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.
Time frame: Date treatment consent signed to date off study, approximately 142 months and 8 days.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 5 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 1 Participants |
| Vandetanib 100 mg/m^2 | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 5 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 1 Participants |
| Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 1 Participants |
| Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 1 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 1 Participants |
| Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 1 Participants |
| Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0) | 1 Participants |
Secondary
Percent Change in Calcitonin (CTN) Biomarker Response After Cycle 1
Blood was collected from participants and measured with an Chemiluminescence immunoassay. Calcitonin upper limit of normal is \<10 pg/mL. A decline in CTN is defined as a ≥50% increase (e.g. tumor growth or progression) in the CTN level after treatment in cycle 1.
Time frame: Cycle 1 (28 days)
Population: This data was only analyzed after cycle 1 and was not collected from the patient who received 150mg/m\^2 dosing during cycle 1. All other patients received 100mg/m\^2 dosing during cycle 1.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Participants | Percent Change in Calcitonin (CTN) Biomarker Response After Cycle 1 | -59 percent change in calcitonin |
Other Pre-specified
Number of Participants With a Dose Limiting Toxicity (DLT)
Hematologic Dose-Limiting Toxicity (H-DLT) is: Neutrophil count below 1,000/μL (grade 3) on 2 consecutive measurements drawn at least 72 hours apart OR a single neutrophil count below 500/μL (grade 4); Platelet count below 50,000/μL (grade 3) on 2 consecutive measurements drawn at least 72 hours apart OR a single platelet count below 25,000/μL (grade 4); A platelet transfusion administered when platelet count is below 50,000/μL is dose limiting thrombocytopenia, unless the transfusion is being administered for perioperative coverage; Grade 3 or 4 decrease in hemoglobin that can be corrected to at least 8.0 g/dl (grade 2) by transfusion of red blood cells is not a dose-limiting toxicity. Grade 3 or 4 hemolysis is a dose-limiting toxicity if it is judged to be vandetanib-related. Non-Hematologic Dose-Limiting Toxicity is any grade 3 or higher non-hematologic toxicity, with some exceptions such as Grade 3 nausea that is controlled by symptomatic treatment with anti-emetics.
Time frame: up to Cycle 3 (each Cycle is 28 days)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| All Participants | Number of Participants With a Dose Limiting Toxicity (DLT) | 1 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 67mg | Number of Participants With a Dose Limiting Toxicity (DLT) | 0 Participants |
| Vandetanib 100 mg/m^2 | Number of Participants With a Dose Limiting Toxicity (DLT) | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 100mg | Number of Participants With a Dose Limiting Toxicity (DLT) | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 63mg, 42, 21, 42, & 21mg/m^2 | Number of Participants With a Dose Limiting Toxicity (DLT) | 0 Participants |
| Vandetanib: First 100 mg/m^2, Then 70 mg/m^2 | Number of Participants With a Dose Limiting Toxicity (DLT) | 0 Participants |
| Vandetanib: First 100mg/m^2, Then 150mg/m^2, Followed by 200mg | Number of Participants With a Dose Limiting Toxicity (DLT) | 0 Participants |
| Vandetanib:First 100mg/m^2, Then 150mg, 100, 150, 100, 150mg | Number of Participants With a Dose Limiting Toxicity (DLT) | 0 Participants |
| Vandetanib: First 150mg/m^2, Then 100mg/m^2, Followed by 150mg | Number of Participants With a Dose Limiting Toxicity (DLT) | 0 Participants |